A novel nano-drug delivery system of glycyrrhetinic acid-mediated intracellular breakable brucine for enhanced anti-hepatitis B efficacy

• Published in: Journal of biomaterials applications 2024-08, Vol.39 (2), p.150-161
• Main Authors: Guan, Qingxia, Liu, Yumeng, Xia, Zhaorui, Zhang, Yue, Wang, Liping, Wang, Yanhong, Zou, Shujun, Lv, Shaowa, Zhou, Xiaoying
• Format: Article
• Language: English
• Subjects: Animals; Antiviral Agents - administration & dosage; Antiviral Agents - chemistry; Antiviral Agents - pharmacology; Glycyrrhetinic Acid - analogs & derivatives; Glycyrrhetinic Acid - chemistry; Glycyrrhetinic Acid - pharmacology; Hep G2 Cells; Hepatitis B - drug therapy; Humans; Liver - drug effects; Liver - metabolism; Male; Nanoparticle Drug Delivery System - chemistry; Rats; Rats, Sprague-Dawley; Strychnine - administration & dosage; Strychnine - analogs & derivatives; Strychnine - chemistry; Strychnine - pharmacology
• ISSN: 0885-3282; 1530-8022; 1530-8022
• DOI: 10.1177/08853282241254750

Background: Glycyrrhetinic acid-mediated brucine self-assembled nanomicelles enhance the anti-hepatitis B properties of brucine by improving its water solubility, short half-life, toxicity, and side effects. Brucine (B) is an indole alkaloid extracted from the seeds of Strychnos nux-vomica (Loganiaceae). Purpose: To assess the efficacy of the Brucine-Glycyrrhetnic acid-Polyethylene glycol-3,3’-dithiodipropionic acid-Glycerin monostearate (B-GPSG) in treating hepatitis B, its potential to protect against acute liver injury caused by d-galactosamine and its anti-hepatoma activities were studied. Research Design: The concentration of B-GPSG used in the in vivo and in vitro experiments was 0.63 mg/mL. The rats injected with d-GalN (450 mg/kg) were used as liver injury models. The rats were separated into normal, model, positive, positive control, B-PSG and B-GPSG groups. Hepatoma cells expressing HBV HepG2.2.15 were used for in vitro experiments. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, plate cloning, Hoechst staining and flow cytometry were conducted to explore the mechanism of B-GPSG against hepatitis B. Results: Compared with the model group, the liver coefficient of B-GPSG group decreased (4.59 ± 0.17 vs 5.88 ± 0.42), the content of MDA in rat liver homogenate decreased (12.54 ± 1.81 vs 23.05 ± 2.98), the activity of SOD increased, the activity of ALT and AST in rat serum decreased. In vitro, the IC50 values of B-GPSG group decreased. B-GPSG group effectively inhibited the proliferation and migration of HepG2.2.15 cells. Conclusions: The hepatoprotective effects of B-GPSG nanomicelles, which are attributed to their GA-mediated liver targeting and synergistic actions with brucine, suggest their therapeutic potential against hepatitis B. This development opens up new possibilities for the application of traditional Chinese medicine and nanomedicine in anti-hepatitis B.